• Refine your search:
  • 
    Keyword:
    
    • Humans (26)
    • Female (14)
    • Aged (9)
    • Drug Therapy (9)
    • Male (9)
    • Middle Aged (8)
    • Combination (6)
    • Child (5)
    • Double-Blind Method (5)
    • Drug Resistance (4)
    •   more
  • 
    Creator / Publisher:
    
    • Chen, B. (4)
    • Licata, A. (4)
    • Melnichenko, G. (4)
    • Miller, S. (4)
    • Saltevo, J. (4)
    • Zalevskaya, A. (4)
    • Adachi, J. (3)
    • Adami, S. (3)
    • Arakaki, R. (3)
    • Badariene, J. (3)
    •   more
  • 
    Year:
    
    • 2022 (1)
    • 2021 (1)
    • 2018 (2)
    • 2015 (3)
    • 2013 (4)
    • 2012 (5)
    • 2011 (2)
    • 2010 (3)
    • 2009 (3)
    • 2008 (3)
    • 2005 (1)
    • 2004 (2)
    • 2001 (2)
    • 1999 (1)
    • 1998 (1)
    • 1993 (1)
    • 1991 (1)
    • 1988 (1)
  • 
    Medium:
    
    • Online (37)
  • 
    Type
  • 
    BLLDB-Access:
    • free (37)
    • subject to license (0)

Search in the Catalogues and Directories

All fields Title Creator / Publisher Keyword Year AND OR AND NOT All fields Title Creator / Publisher Keyword Year AND OR AND NOT All fields Title Creator / Publisher Keyword Year AND OR AND NOT All fields Title Creator / Publisher Keyword Year AND OR AND NOT All fields Title Creator / Publisher Keyword Year Sort by creator [A → Z]' creator [Z → A]' publishing year ↑ (asc)' publishing year ↓ (desc)' title [A → Z]' title [Z → A]' Simple Search Page: 1 2 Hits 1 – 20 of 37 1 Facilitators and barriers of women's participation in HIV clinical research in Switzerland: A qualitative study. Courvoisier, N.; Storari, C.; Lesage, S.... In: HIV medicine, vol. 23, no. 4, pp. 441-447 (2022) BASE Show details 2 A Therapeutic Relational Agent for Reducing Problematic Substance Use (Woebot): Development and Usability Study. Prochaska, Judith J; Vogel, Erin A; Chieng, Amy... In: Journal of medical Internet research, vol 23, iss 3 (2021) BASE Show details 3 New Directions in Treatments Targeting Stroke Recovery. Lin, David J; Finklestein, Seth P; Cramer, Steven C In: Stroke, vol 49, iss 12 (2018) BASE Show details 4 Cognitive Working Memory Training (CWMT) in adolescents suffering from Attention-Deficit/Hyperactivity Disorder (ADHD): A controlled trial taking into account concomitant medication effects. Ackermann, S.; Halfon, O.; Fornari, E.... In: Psychiatry research, vol. 269, pp. 79-85 (2018) BASE Show details 5 Refractory depression: mechanisms and evaluation of radically open dialectical behaviour therapy (RO-DBT) [REFRAMED]: protocol for randomised trial. Lynch, TR; Whalley, B; Hempel, RJ. - : BMJ Publishing Group, 2015 BASE Show details 6 Painful oral aphthous-like lesions in patient with kidney cancer after target therapy and bisphosphonate administration: a case report of adverse drug reaction. Mauceri, R; Di Fede, O; Perrone,D. - : Edizioni Minerva Medica, 2015. : country:IT, 2015 BASE Show details 7 Refractory depression: mechanisms and evaluation of radically open dialectical behaviour therapy (RO-DBT) [REFRAMED]: protocol for randomised trial. Lynch, TR; Whalley, B; Hempel, RJ. - : England, 2015 BASE Show details 8 Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial Wietecha, Linda; Williams, David; Shaywitz, Sally... In: PMC (2013) BASE Show details 9 Innovative solutions to novel drug development in mental health. Insel, TR; Voon, V; Nye, JS... In: Symplectic Elements at Oxford ; Europe PubMed Central ; PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) ; Web of Science (Lite) (http://apps.webofknowledge.com/summary.do) ; Scopus (http://www.scopus.com/home.url) ; CrossRef (2013) BASE Show details 10 Innovative solutions to novel drug development in mental health. Insel, TR; Voon, V; Nye, JS... In: Neurosci Biobehav Rev , 37 (10 Pt 1) pp. 2438-2444. (2013) (2013) BASE Show details 11 An evaluation of the parents under pressure programme: a study protocol for an RCT into its clinical and cost effectiveness Barlow, Jane; Sembi, Sukhdev; Gardner, Frances. - : BioMed Central, 2013 BASE Show details 12 Research Article ASSESSMENT OF COLLEGE STUDENT’S AWARENESS ABOUT TUBERCULOSIS IN AHMEDNAGAR Sagar D. Kadam; Anjum Shaikh; Pinky Bhati... In: http://www.ijrdpl.com/docs/5th/6 Res.pdf (2012) BASE Show details 13 Association between ambulatory 24-hour blood pressure levels and brain volume reduction: a cross-sectional elderly population-based study Celle, Sébastien; Annweiler, Cédric; Pichot, V.... In: ISSN: 1524-4563 ; Hypertension (Dallas, Tex. : 1979) ; https://hal.univ-angers.fr/hal-03355591 ; Hypertension (Dallas, Tex. : 1979), 2012, 60 (5), pp.1324-31. &#x27E8;10.1161/hypertensionaha.112.193409&#x27E9; (2012) BASE Show details 14 Basal insulin and cardiovascular and other outcomes in dysglycemia. Gerstein, H.C.; Bosch, J.; Dagenais, G.R.... In: New England Journal of Medicine, vol. 367, no. 4, pp. 319-328 (2012) BASE Show details 15 n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. Bosch, J.; Gerstein, H.C.; Dagenais, G.R.... In: New England Journal of Medicine, vol. 367, no. 4, pp. 309-318 (2012) BASE Show details 16 Cardiorenal end points in a trial of aliskiren for type 2 diabetes. Parving, H.H.; Brenner, B.M.; McMurray, J.J.; de Zeeuw, D.; Haffner, S.M.; Solomon, S.D.; Chaturvedi, N.; Persson, F.; Desai, A.S.; Nicolaides, M.; Richard, A.; Xiang, Z.; Brunel, P.; Pfeffer, M.A. In: New England Journal of Medicine, vol. 367, no. 23, pp. 2204-2213 (2012) Abstract: BACKGROUND: This study was undertaken to determine whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease, cardiovascular disease, or both. METHODS: In a double-blind fashion, we randomly assigned 8561 patients to aliskiren (300 mg daily) or placebo as an adjunct to an angiotensin-converting-enzyme inhibitor or an angiotensin-receptor blocker. The primary end point was a composite of the time to cardiovascular death or a first occurrence of cardiac arrest with resuscitation; nonfatal myocardial infarction; nonfatal stroke; unplanned hospitalization for heart failure; end-stage renal disease, death attributable to kidney failure, or the need for renal-replacement therapy with no dialysis or transplantation available or initiated; or doubling of the baseline serum creatinine level. RESULTS: The trial was stopped prematurely after the second interim efficacy analysis. After a median follow-up of 32.9 months, the primary end point had occurred in 783 patients (18.3%) assigned to aliskiren as compared with 732 (17.1%) assigned to placebo (hazard ratio, 1.08; 95% confidence interval [CI], 0.98 to 1.20; P=0.12). Effects on secondary renal end points were similar. Systolic and diastolic blood pressures were lower with aliskiren (between-group differences, 1.3 and 0.6 mm Hg, respectively) and the mean reduction in the urinary albumin-to-creatinine ratio was greater (between-group difference, 14 percentage points; 95% CI, 11 to 17). The proportion of patients with hyperkalemia (serum potassium level, ≥6 mmol per liter) was significantly higher in the aliskiren group than in the placebo group (11.2% vs. 7.2%), as was the proportion with reported hypotension (12.1% vs. 8.3%) (P<0.001 for both comparisons). CONCLUSIONS: The addition of aliskiren to standard therapy with renin-angiotensin system blockade in patients with type 2 diabetes who are at high risk for cardiovascular and renal events is not supported by these data and may even be harmful. (Funded by Novartis; ALTITUDE ClinicalTrials.gov number, NCT00549757.). Keyword: Aged; Amides/adverse effects; Amides/therapeutic use; Angiotensin Receptor Antagonists/therapeutic use; Angiotensin-Converting Enzyme Inhibitors/therapeutic use; Antihypertensive Agents/adverse effects; Antihypertensive Agents/therapeutic use; Cardiovascular Diseases/epidemiology; Cardiovascular Diseases/mortality; Combination; Diabetes Mellitus; Double-Blind Method; Drug Therapy; Female; Follow-Up Studies; Fumarates/adverse effects; Fumarates/therapeutic use; Humans; Hyperkalemia/chemically induced; Hypokalemia; Kidney Diseases/epidemiology; Kidney Diseases/etiology; Male; Middle Aged; Patient Dropouts; Renin/antagonists & inhibitors; Treatment Failure; Type 2/complications; Type 2/drug therapy URL: https://serval.unil.ch/notice/serval:BIB_AA678180CBF9 https://doi.org/10.1056/NEJMoa1208799 BASE Hide details 17 Crossover trial of subacute computerized aphasia therapy for anomia with the addition of either levodopa or placebo Leemann, Béatrice; Laganaro, Marina; Chetelat-Mabillard, Daphné... In: ISSN: 1545-9683 ; Neurorehabilitation and Neural Repair, Vol. 25, No 1 (2011) pp. 43-47 (2011) BASE Show details 18 Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial. Cauley, J.A.; Black, D.; Boonen, S.... In: Journal of Bone and Mineral Research, vol. 26, no. 5, pp. 984-992 (2011) BASE Show details 19 Nova Scotia Medical Bulletin 5(4), 1926 Medical Society of Nova Scotia. - : Halifax, Medical Society of Nova Scotia, 2010 BASE Show details 20 Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial. Eastell, R.; Lang, T.; Boonen, S.... In: Osteoporosis International, vol. 21, no. 7, pp. 1277-1285 (2010) BASE Show details Page: 1 2

Mobile view All Catalogues UB Frankfurt Linguistik 0 IDS Mannheim 0 OLC Linguistik 0 UB Frankfurt Retrokatalog 0 DNB Subject Category Language 0 Institut für Empirische Sprachwissenschaft 0 Leibniz-Centre General Linguistics (ZAS) 0 Bibliographies BLLDB 0 BDSL 0 IDS Bibliografie zur deutschen Grammatik 0 IDS Bibliografie zur Gesprächsforschung 0 IDS Konnektoren im Deutschen 0 IDS Präpositionen im Deutschen 0 IDS OBELEX meta 0 MPI-SHH Linguistics Collection 0 MPI for Psycholinguistics 0 Linked Open Data catalogues Annohub 0 Online resources Link directory 0 Journal directory 0 Database directory 0 Dictionary directory 0 Open access documents BASE 37 Linguistik-Repository 0 IDS Publikationsserver 0 Online dissertations 0 Language Description Heritage 0